Furthermore, statins can overcome EGFR-TKI resistance in patients with lung cancer harboring KRAS mutation, and they provided an increased response rate in lung cancer patients previously treated with nivolumab [37,38]. The gene discussed is KRAS; the disease is lung carcinoma.